ArticlePloS one2025
TRIM6 affects the prognosis of acute myeloid leukemia through the PI3K/AKT signaling pathway and is associated with immune infiltration.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute Myeloid Leukemia (AML) is a heterogeneous disease with limited therapeutic options and poor prognosis for patients. Therefore, the aim of this study was to evaluate the potential value of TRIM6 as a prognostic marker in AML.
methodsIn this study, the low-expressed gene TRIM6 was obtained by analysis of The Cancer Genome Atlas (TCGA-AML) and Genotype-Tissue Expression (GTEx) databases.The prognostic impact of TRIM6 was analyzed using Kaplan-Meier curves, univariate COX, multivariate COX, and columnar plot models. The signaling pathways associated with TRIM6 were obtained using Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) methods. Infiltrating immune cells associated with TRIM6 expression were analyzed using the "CIBERSORT" method. Mutations in AML patients were characterized using relevant Single Nucleotide Polymorphism (SNP) data. The effect of TRIM6 expression on AML cell progression was further analyzed by qRT-PCR, CCK-8 assay, flow cytometry and Western blot.
resultsBy analyzing TCGA-AML and GTEx data, TRIM6 was found to be under-expressed in AML patients, and Kaplan-Meier curves, one-way and multifactorial Cox regression models suggested that under-expression of TRIM6 had a poor prognosis. In addition, monocyte, M2 macrophage and memory B cell infiltration levels were found to be higher in the TRIM6 low-expression group than in the TRIM6 high-expression group based on the "CIBERSORT" method. Further mutational characterization showed that TRIM6 expression was positively correlated with NPM1 mutations and negatively correlated with mutations in RUNX1, TP53 and ASXL1. Enrichment analysis revealed that TRIM6 expression was associated with the PI3K/AKT signaling pathway and immune response. In addition, in vivo and in vitro experiments further demonstrated that TRIM6 expression could inhibit AML progression via PI3K/AKT.
conclusionTRIM6 is expressed at low levels in AML, correlates with immune infiltration, and may affect AML progression through the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.